|1.||Newman-Tancredi, Adrian: 3 articles (10/2009 - 09/2008)|
|2.||Newman-Tancredi, A: 3 articles (05/2007 - 05/2007)|
|3.||Vacher, B: 3 articles (05/2007 - 05/2007)|
|4.||Colpaert, F: 3 articles (05/2007 - 05/2007)|
|5.||Bardin, Laurent: 2 articles (11/2008 - 09/2008)|
|6.||Depoortère, R: 2 articles (05/2007 - 05/2007)|
|7.||Kleven, M S: 2 articles (05/2007 - 05/2007)|
|8.||Auclair, A L: 2 articles (05/2007 - 05/2007)|
|9.||Bardin, L: 2 articles (05/2007 - 05/2007)|
|10.||Bruins Slot, Liesbeth A: 1 article (10/2009)|
|1.||Schizophrenia (Dementia Praecox)
05/01/2007 - "Here, the profile of F15063 was evaluated in models of positive symptoms of schizophrenia and motor side-effects. "
05/01/2007 - "The D(2)/D(3) receptor antagonist, D(4) receptor partial agonist, and high efficacy 5-HT(1A) receptor agonist F15063 was shown to be highly efficacious and potent in rodent models of activity against positive symptoms of schizophrenia. "
05/01/2007 - "F15063 antagonised dopamine D(2)/D(3) receptors, a property underlying its antipsychotic-like activity, whereas activation of 5-HT(1A) and D(4) receptors mediated its actions in models of negative symptoms and cognitive deficits of schizophrenia (see companion papers)."
05/01/2007 - "The balance of D(2)/D(3), D(4) and 5-HT(1A) receptor interactions of F15063 yields a promising profile of activity in models of cognitive deficits and negative symptoms of schizophrenia."
10/12/2009 - "F15063 (10 mg/kg) and clozapine (10 mg/kg), but not haloperidol (0.63 mg/kg), induced c-fos and fosB mRNA expression in prefrontal cortex, a region associated with control of cognition and negative symptoms of schizophrenia. "
05/01/2007 - "F15063 conformed to the profile of an atypical antipsychotic, with potent actions in models of hyperdopaminergic activity but without inducing catalepsy. "
05/01/2007 - "F15063, owing to its 5-HT(1A) agonism, did not produce (ED(50)>40 mg kg(-1) i.p.) catalepsy in rats and mice, a behavior predictive of occurrence of extra-pyramidal syndrome (EPS) in man. "
05/01/2007 - "However F15063 induced neither catalepsy nor the 'serotonin syndrome'. "
10/12/2009 - "In striatum, only c-fos, fosB, junB and nur77 were induced by clozapine whereas all IEG mRNAs were increased by haloperidol and F15063 (from 2.5 mg/kg) with similar high efficacy despite a total absence of F15063-induced catalepsy. "
|3.||Serotonin Syndrome (Syndrome, Serotonin)
09/11/2008 - "A variety of mechanisms likely underlie the hyperglycemia and corticosterone release observed with clozapine and olanzapine, whilst the balance of dopamine D2/3/5-HT1A interaction may contribute to the less favourable impact of SLV313 and SSR181507 compared with that of bifeprunox and F15063."
|1.||5-HT1A Serotonin Receptor
|4.||1- (2,3- dihydro- 1,4- benzodioxin- 5- yl)- 4- ((5- (4- fluorophenyl)- 3- pyridinyl)methyl)piperazine
|5.||Risperidone (Risperdal Consta)
|8.||Messenger RNA (mRNA)